<< Back
Stereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance
September 23, 2015 at 9:02 AM EDT
Vmotion Features Enhance V-Sono(TM) System Capabilities

ST. LOUIS, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first procedures performed in the U.S. with its Vmotion suite of automation features. Cleared by the FDA this past June, Vmotion enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE) catheter in conjunction with the V-Sono™ ICE catheter manipulator.

Widely used in the U.S., particularly with atrial fibrillation cases, the ICE catheter provides ultrasound imaging of the heart during electrophysiology (EP) procedures. The Vdrive™ with V-Sono system, released in the U.S. in 2013, remotely controls an ICE catheter in a Niobe® ES remote magnetic navigation enabled procedure. The V-Sono system can improve patient outcomes through more precise, stable ultrasound imaging and reduces radiation exposure to the EP team by eliminating the need for manual ICE manipulation within the radiation field. Vmotion supports the V-Sono manipulator functionality through three unique automation features: Spotlight, which continually keeps the ablation catheter tip within the ICE viewing plane automatically; Stored Positions, which allows for positions of the ICE catheter to be recalled and returned to throughout the procedure; and Sweep, which enables the ultrasound field of view to continuously sweep across an area of interest defined by the user.

"The combination of Vmotion and the V-Sono system greatly enhances my ability to visualize, in real-time, the tip-to-tissue contact of the ablation catheter throughout procedures using the Niobe system," said Michael Porter, M.D., Exempla Saint Joseph Hospital in Denver, CO. "This is a significant advancement in improving the effectiveness of therapy delivery and reducing reliance on fluoroscopy. Stereotaxis continually delivers on its promise to support EP physicians with groundbreaking products and features that allow us to focus on patients rather than the complex mechanics of the ablation procedure."

To date, the Vmotion suite has been installed in two U.S. sites, Exempla Saint Joseph Hospital and Advocate Christ Medical Center in Oak Lawn, IL.  

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.

The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect", or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period, or at all, because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

CONTACT: STXS Company Contact:
         Martin Stammer
         Chief Financial Officer

         STXS Investor Contact:
         Todd Kehrli / Jim ByersMKR Group, Inc.

Stereotaxis logo

Stereotaxis, Inc.
© Copyright Stereotaxis 2020